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Abstract
Due to the chronic nature of diabetes along with their complications, they have been recog-
nised as a major health issue, which results in significant economic burden. This study aims
to estimate the direct medical cost associated with type 2 diabetes mellitus (T2DM) in Sin-
gapore in 2010 and to examine both the relationship between demographic and clinical
state variables with the total estimated expenditure. The National Healthcare Group (NHG)
Chronic Disease Management System (CDMS) database was used to identify patients with
T2DM in the year 2010. DM-attributable costs estimated included hospitalisations, accident
and emergency (A&E) room visits, outpatient physician visits, medications, laboratory tests
and allied health services. All charges and unit costs were provided by the NHG. A total of
500 patients with DM were identified for the analyses. The mean annual direct medical cost
was found to be $2,034, of which 61% was accounted for by inpatient services, 35% by out-
patient services, and 4% by A&E services. Independent determinants of total costs were
DM treatments such as the use of insulin only (p<0.001) and the combination of both oral
medications and insulin (p=0.047) as well as having complications such as cerebrovascular
disease (p<0.001), cardiovascular disease (p=0.002), peripheral vascular disease
(p=0.001), and nephropathy (p=0.041). In this study, the cost of DM treatments and DM-
related complications were found to be strong determinants of costs. This finding suggests
an imperative need to address the economic burden associated with diabetes with urgency
and to reorganise resources required to improve healthcare costs.
Introduction
Globally, the total number of people with diabetes mellitus (DM) is projected to rise from 171
million in 2000 to 366 million in 2030 [1]. There is a growing epidemic of diabetes mellitus,
type 2 in particular, in the Asia-Pacific region [2, 3]. According to current estimates, the DM
population in this region is the largest in the world, with approximately 47.3 million, which is
46% of the global burden of this disease [4]. In Singapore, as in many developed countries, DM
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is a growing public health problem. The prevalence of DM has risen to 12.3% in 2013, from
8.2% in 2004 and 9% in 1998 [5–7], surpassing other Asian countries such as Hong Kong
(9.5%), Japan (7.2%) and Taiwan (5.7%) [8]. Moreover, DM is the tenth leading cause of death
in Singapore, accounting for 1.7% of total deaths in 2011 [9].
Diabetes is a chronic medical condition associated with numerous complications that
makes it a substantial economic burden incurred by individuals, healthcare systems and society
as a whole [10]. In 2007, the global health expenditure to treat and prevent DM and its compli-
cations was estimated to be at least US$232 billion [8]. Depending on available treatments and
local prevalence, the direct costs of DM consume from 2.5% to 15.0% of annual healthcare
budgets [11].
Despite the large number of people with DM, the financial burden in Singapore attributed
to DM has not been investigated. Because type 2 diabetes mellitus (T2DM) accounts for ap-
proximately 90% of DM cases and its prevalence increases with ageing, understanding the pat-
terns of resource use and cost associated with T2DM is becoming increasingly important for
policymakers and budget planners. Therefore, this study aims to identify the total direct medi-
cal cost of T2DM in Singapore and to examine the relationship between direct medical costs
and individual demographic characteristics, DM treatments (exercise or diet, taking oral medi-




This study adopted a prevalence-based ‘epidemiological’ approach, employing a bottom-up
methodology to estimate different cost components. The prevalence approach can yield more
precise estimates because it ascertains the current economic burden of a disease rather than
projected ones [12, 13]. The perspective for this study was that of the healthcare system (i.e.,
National Healthcare Group (NHG) institutions). This study was approved by the National
Healthcare Group Domain Specific Review Board (NHG-DSRB).
Data source
This was a cross-sectional study of T2DM patients who had received care in any of the NHG
institutions in 2010. The NHG is public funded and provides inpatient and ambulatory care
(primary care, specialist outpatient and 24-hour emergency) services through a network of 3
acute hospitals, 1 national center, 9 primary care clinics and 3 specialty institutes serving the
population in the central and western parts of Singapore. The 9 primary care clinics, also
known as polyclinics, had a service load of 3.7 million attendances in 2010, which accounted
for 60% of all public sector primary care attendances [14]. Data was drawn from the NHG
Chronic Disease Management System (CDMS), which serves as an operational disease registry
within the NHG. The CDMS was commissioned in 2007 to enhance the delivery of care for pa-
tients with DM and to facilitate greater efficiency in outcome measurement. It links key clinical
data of patients with DM across the NHG healthcare cluster, including records of visits to phy-
sicians, nurses, and allied health professionals, as well as medication and laboratory test records
[15]. In addition, it also includes registration and financial cost data related to the care of
chronic diseases.
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Patient selection
Patients with T2DM were identified using the International Classification of Diseases Ninth
Revision (ICD-9-CM) with diagnostic code of 250 as primary or secondary diagnosis, or using
pharmacy medication records or laboratory data in the CDMS. Diabetes complications and co-
morbidities were also identified using ICD-9-CM codes, while only DM-related medications
and laboratory data were based on inpatient and outpatient encounters at the hospital or out-
patient clinics that were registered with the CDMS. Systematic sampling was conducted for
98,592 identified DM patients (i.e., every 197th patient was selected). Informed consent was not
obtained from the patients as the data was de-identified prior to analysis.
This study included patients who satisfied at least one of the following three criteria: (1) as-
signed ICD-9-CM code of 250; (2) attended treatment for DM for 1 year in any NHG institu-
tion; or (3) prescribed any anti-diabetic medication. Patients with type 1 DM and women with
gestational diabetes were excluded.
Laboratory-derived measures related to DM
Measures for DM-related physical examinations were included and categorised as follow:
(1) body mass index (BMI) (kg/m2): <18.50 = underweight; 18.50–24.99 = normal;
>25.00 = overweight and obese [16], (2) glycated haemoglobin (HbA1c) (%):7.0 = good dis-
ease control; 7.1–8.0 = sub-optimal disease control;>8.0 = poor disease control, (3) low-
density lipoprotein cholesterol (LDL-c) (mmol/L):<2.6 = optimal; 2.6–4.0 = near optimal;
>4.0 = high, (4) urine albumin-to-creatinine ratio (UACR) (albumin/24h):<30mg = normal;
30-299mg = microalbuminuria; >300mg = macroalbuminuria [17, 18].
Estimation of costs
Direct DM-related costs were classified by the type of service, including inpatient hospitalisa-
tion, accident and emergency (A&E) and ambulatory outpatient care (physician visits, allied
health visits, laboratory tests and medications). Allied health visits include foot screening, eye
screening, dietary services and health education. The total medical costs were estimated by the
total before-subsidy charges, which is the total medical bill before any deduction for govern-
ment subsidies or insurance claims. All costs reported were in Singapore currency (S$) for year
2010 prices.
The cost of inpatient care and A&E services were estimated by the total charge based on the
length of stay and resources used. Any A&E visits that resulted in hospitalisation were included
as inpatient care costs. Unit costs used in the estimation of physician visits, which included vis-
its to primary care clinics (polyclinics) and specialist outpatient clinics (hospitals), were equal
to the standardised rate for physician visits at all NHG primary care clinics and hospitals.
Therefore, costs were estimated by multiplying the number of physician visits by the unit cost
of a visit. Unit costs for allied health visits, laboratory tests and medications were estimated via
the same method as physician visits. The cost for drugs other than anti-diabetic medications
was not included. Unit costs for all services rendered were provided by the NHG and are in Sin-
gapore dollars. Direct non-medical costs, such as transportation expenses and indirect costs
were not included.
Statistical methods
Healthcare cost data are often positively skewed because a relatively small proportion of pa-
tients incur extremely high costs [19, 20]. Such problems were dealt with by logarithmic trans-
formation of the cost data [21]. Descriptive statistics (frequency, percentage, mean, median,
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standard deviation and 90th percentile) were used for demographic information and expendi-
tures. To identify the factors affecting total costs, a multiple linear regression model was devel-
oped to evaluate the relationship of both demographic and clinical state variables (HbA1c, DM
treatments, complications and comorbidities) to the total calculated expenditure. All statistical
analyses were performed using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
A total of 98,592 patients in the NHG CDMS (2010) were identified as patients with DM. After
applying the selection criteria and a systematic sampling, 500 patients were included in the
analyses. The socio-demographic profile of the patients is shown in Table 1. The patients were
equally distributed between the two genders (55.4% female). The mean (±SD) age was
69.0 ± 9.4 years, and most study patients were Chinese (77.6%) and non-smokers (89.8%). Al-
though a greater proportion of patients was overweight (42.6%), most had good disease control
(44.6%), optimal LDL-c (43.2%) and normal UACR (41.2%). Of the 69.2% of DM patients who
were on anti-diabetic medications, the majority used oral medications (57.2%), while only 3%
were treated with insulin and the remaining 9% used both insulin and oral medications. Ne-
phropathy (57.2%) and cardiovascular conditions (34.2%) were common DM complications
among the cohort. The distributions of subgroups were similar between patients with at least
one inpatient visit and those without any inpatient visit.
Annual costs of diabetes
The mean annual direct cost was S$2,034.6 (US$1.0 = S$1.3 as of 31 December 2010) [22], of
which S$1,237.2 accounted for by inpatient services, S$84.2 by A&E services and S$713.2 by
outpatient services (Table 2). Of the total healthcare expenditure, the main cost driver was in-
patient costs (60.8%), while A&E services (4.1%) were only a small portion of the total costs.
The major source of costs for outpatient services was physician visits, which accounted for
22.6% of the total healthcare expenditure and 64.0% of total outpatient expenditure (Fig. 1).
Patients with at least one inpatient admission had higher mean total costs (S$8,787.8) than
those who had no inpatient admission (S$690.5), with the bulk of costs resulting from inpatient
services (S$7,453.3). Conversely, patients with no inpatient visits had a substantially higher
proportion of overall outpatient costs.
Factors affecting the total costs
Using multiple linear regression with log transformation, the total cost of DM was significantly
associated with DM treatments (taking insulin only or both oral medications and insulin) and
DM-related complications (cerebrovascular, cardiovascular, and peripheral vascular diseases
and nephropathy). This model explained 23.0% of the variance in costs (Table 3). Age, gender,
race, smoking status, disease control, taking only oral medication, having retinopathy and co-
morbidities were not independently associated with cost. The combination of oral medications
and insulin resulted in an average increment in annual total cost (17.5%, p = 0.047), while the
use of only insulin led to a higher increment (53.2%, p<0.001) when compared with patients
who were only on dietary control and healthy lifestyle advice alone. Taking the absence of com-
plications as reference, the cost of DM was higher when complications were present except in
the case of retinopathy.
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Table 1. Socio-demographic and clinical characteristics of patients with diabetesmellitus, CDMS 2010.
Characteristic n (%)a or mean ± standard deviation





Age (years) 69.0 ±9.4 71.7 ±9.5 68.8 ±9.3
Gender
Female 277 (55.4) 45 (54.2) 185 (55.6)
Male 223 (44.6) 38 (45.8) 232 (44.4)
Race
Chinese 388 (77.6) 61 (73.5) 327 (78.4)
Malay 57 (11.4) 10 (12.0) 47 (11.3)
Indian 34 (6.8) 6 (7.2) 28 (6.7)
Others 21 (4.2) 6 (7.2) 15 (3.6)
Smoking status
Non-smoker 449 (89.8) 75 (90.4) 374 (89.7)
Smoker 51 (10.2) 8 (9.6) 43 (10.3)
Physical examination
BMI (kg/m2) (n = 378)1 (n = 45)2 (n = 333)3 26.1 ±4.7 26.0 ±5.0 26.1 ±4.6
Underweight 7 (1.4) 2 (2.4) 5 (1.2)
Normal 158 (31.6) 16 (19.3) 142 (34.1)
Overweight 213 (42.6) 27 (32.5) 186 (44.6)
Blood pressure (mmHg) (n = 414)1 (n = 56)2 (n = 358)3
Systolic 132.2 ±14.0 134.9 ±17.1 131.8 ±13.4
Diastolic 70.4 ±7.5 71.2 ±9.3 70.3 ±7.2
HbA1c (%) (n = 441)1 (n = 73)2 (n = 368)3 7.3 ±1.2 7.3 ±1.5 7.3 ±1.2
Good disease control 223 (44.6) 37 (44.6) 186 (44.6)
Sub-optimal disease control 134 (26.8) 19 (22.9) 115 (27.6)
Poor disease control 84 (16.8) 17 (20.5) 67 (16.1)
LDL-c level (mmol/L) (n = 398)1 (n = 61)2 (n = 337)3 2.6 ±0.8 2.7 ±1.1 2.6 ±0.7
Optimal 216 (43.2) 35 (42.2) 181 (43.4)
Near optimal 169 (33.8) 23 (27.7) 146 (35.0)
High 13 (2.6) 3 (3.6) 10 (2.4)
Serum creatinine (μmol/L) (n = 424)1 (n = 81)2 (n = 343)3 102.1 ±87.6 137.0 ±145.4 93.9 ±64.8
UACR (n = 321)1 (n = 39)2 (n = 282)3
Normal 206 (41.2) 15 (18.1) 191 (45.8)
Microalbuminuria 94 (18.8) 20 (24.1) 74 (17.7)
Macroalbuminuria 21 (4.2) 4 (4.8) 17 (4.1)
Diabetes treatment
Diet or exercise only 154 (30.8) 27 (32.5) 127 (30.5)
Oral anti-diabetic medication only 286 (57.2) 42 (50.6) 244 (58.5)
Insulin only 15 (3.0) 8 (9.6) 7 (1.7)
Oral and insulin 45 (9.0) 6 (7.2) 39 (9.4)
Diabetes complications
Nephropathy 286 (57.2) 63 (75.9) 223 (53.5)
Cardiovascular 171 (34.2) 49 (59.0) 122 (29.3)
Retinopathy 75 (15.0) 24 (28.9) 51 (12.2)
Peripheral vascular disease 73 (14.6) 27 (32.5) 46 (11.0)
Cerebrovascular 71 (14.2) 32 (38.6) 39 (9.4)
(Continued)
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Table 1. (Continued)
Characteristic n (%)a or mean ± standard deviation





Dyslipidaemia 483 (96.6) 77 (92.8) 406 (97.4)
Hypertension 441 (88.2) 81 (97.6) 360 (86.3)
a Percentages may not add up to 100% due to missing values
b n = 500 otherwise stated in the brackets
c n = 83 otherwise stated in the brackets
d n = 417 otherwise stated in the brackets
BMI = body mass index, HbA1c = glycated haemoglobin, LDL-c = low-density lipoprotein cholesterol, UACR = urine albumin-to-creatinine ratio
doi:10.1371/journal.pone.0122795.t001
Table 2. Direct medical costs of diabetesmellitus paid by the hospital.
Costs variables Total (S$) %a Mean SD Median 90th percentile
Overall (n = 500)
Inpatient costs 618,622.0 60.8 1,237.2 ± 4,085.8 0.0 2,846.4
Accident & Emergency 42,084.4 4.1 84.2 ± 277.6 0.0 300.4
Outpatient costs 356,600.8 35.1
Physician visit 229,506.0 22.6 459.0 ± 396.8 325.0 974.0
Allied health service 10,061.0 1.0 20.1 ± 30.0 19.6 40.8
Laboratory tests 35,990.0 3.5 72.0 ± 52.5 68.9 114.3
Medications 81,043.9 8.0 162.1 ± 220.4 101.0 377.5
Total 1,017,306.2 2,034.6 ± 4,351.0 664.1 4,209.6
 1 inpatient visit (n = 83)
Inpatient costs 618,621.0 84.8 7,453.3 ± 7,395.5 3,740.5 16,858.9
Accident & Emergency 33,745.6 4.6 406.6 ± 550.2 301.2 722.4
Outpatient costs 77,021.4 10.6
Physician visit 57,851.0 7.9 697.0 ± 479.0 612.0 1,344.4
Allied health service 2,022.9 0.3 24.4 ± 50.0 0.0 52.3
Laboratory tests 5,523.2 0.8 66.5 ± 63.3 58.2 154.5
Medications 11,624.3 1.6 140.1 ± 232.2 62.0 302.4
Total 729,388.0 8,787.8 ± 7,660.1 5,160.4 18,322.6
0 inpatient visit (n = 417)
Accident & Emergency 8,338.8 2.9 20.0 ± 88.9 0.0 0.0
Outpatient costs 279,579.4 97.1
Physician visit 171,655.0 59.6 411.6 ± 360.7 296.0 834.2
Allied health service 8,038.0 2.8 19.3 ± 24.1 19.6 35.4
Laboratory tests 30,466.7 10.6 73.1 ± 50.1 70.9 108.2
Medications 69,419.6 24.1 166.5 ± 218.0 114.7 386.7
Total 287,918.2 690.5 ± 481.3 588.2 1,200.6
a Percentages may not add up to 100% due to missing values
doi:10.1371/journal.pone.0122795.t002
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Discussion
This prevalence-based cost-of-illness study involved a large captive population with T2DM in
Singapore. The analysis was based on cost and administrative data retrieved from the NHG dis-
ease registry for 2010. This is the first study to provide estimates of costs associated with diabe-
tes care in Singapore.
The cost per patient estimate in this present study was S$2,034.6 (US$1,575.6), and this ap-
pears to be higher than the costs reported in other Asian countries. A study in India reported
an estimate of US$525.5 per patient [23], while a study in China reported costs of US$1,501.7
per patient [11] for the management of DM. However, the costs reported in these studies were
presented without accounting for inflation or difference between currency. Notably, hospital
costs reported in the American and European continents were much higher than those ob-
tained in this study [24–26]. Despite the cost differences, inpatient costs still remained the
main cost driver of the total estimated expenditure, which was also noted in the earlier DM
COI studies [25, 27–29]. Although the length of stay (LOS) was not reported in this study, the
high cost of inpatient services were often strongly correlated to LOS [30, 31], with higher LOS
resulting in higher costs. This suggested that attempts to expedite services or reduce unneces-
sary utilisation of diagnostic tests to reduce LOS may be worthwhile in reducing overall costs.
In terms of outpatients costs, physician services contributed to the bulk of the total expendi-
ture in our study, and this was understandable since the growth in the number of physicians
and specialists have increased over the years to meet with higher patient demands [32]. In addi-
tion, the introduction of new medical technologies and prescription drugs have also shown sig-
nificant association with physician cost growth because consumers generally require physician
visits to obtain diagnostic tests and prescriptions [32]. Because physicians are central to the
healthcare system, efforts to contain physician spending reverberate through all healthcare ser-
vices, especially with DM being a chronic condition requiring continuous follow-ups.
Our results from the regression analyses have generally confirmed what might have been ex-
pected based on the epidemiologic evidence in the literature [11, 20, 33–35], that microvascular
and macrovascular complications tend to increase the cost of care. On the contrary, comorbidi-
ties such as hypertension and dyslipidaemia did not have an association with overall cost. This
Fig 1. Components of outpatient costs.
doi:10.1371/journal.pone.0122795.g001
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result is surprising since cost-effectiveness and medication adherence studies [36–39] have re-
ported that achieving therapeutic clinical parameters would lead to an increase in cost of care
albeit increasing the quality-adjusted life years (QALY). A possible explanation could be that
hypertension and dyslipidaemia may have been controlled or at a steady state that did not re-
quire treatment, resulting in no costs incurred.
In our study, patients with sub-optimal and poor disease control had lower overall costs.
This may be due to underutilisation of healthcare services compared to those with good disease
control. The importance of managing DM to prevent or delay complications requires effort
[40] and good control of DM results in long-term cost savings due to fewer complications [41].
Furthermore, The use of insulin only or both insulin and oral antidiabetic medications were
Table 3. Factors influencing the total annual cost of diabetes (n = 500)a.
Characteristic β-coefﬁcient 95% CI P value
Individual level factors
Age (per year increase) 0.000 -0.004 0.005 0.900
Gender
Male (reference)
Female 0.034 -0.047 0.114 0.412
Race
Chinese (reference) 0.000
Malay 0.102 -0.021 0.225 0.104
Indian 0.039 -0.120 0.198 0.632
Others 0.143 -0.050 0.336 0.146
Smoking status
Non-smoker (reference)
Smoker -0.043 -0.178 0.091 0.528
Physical examination
HbA1c (%) (n = 441)
Good disease control (reference)
Sub-optimal disease control 0.001 -0.097 0.098 0.989
Poor disease control 0.066 -0.055 0.187 0.286
Diabetes treatment
Diet or exercise only (reference)
Oral medication only 0.079 -0.024 0.182 0.132
Insulin only 0.532 0.276 0.788 <0.001
Oral and insulin 0.175 0.002 0.348 0.047
Diabetes complications (Absent reference)
Cerebrovascular 0.310 0.189 0.430 <0.001
Cardiovascular 0.150 0.054 0.245 0.002
Peripheral vascular disease 0.207 0.088 0.325 0.001
Nephropathy 0.123 0.005 0.240 0.041
Retinopathy 0.046 -0.070 0.161 0.436
Diabetes comorbidity
None (reference)
Either hypertension or dyslipidaemia 0.114 -0.101 0.328 0.298
Both hypertension and dyslipidaemia 0.071 -0.077 0.219 0.348
a n = 500 otherwise stated in the brackets
HbA1c = glycated haemoglobin
doi:10.1371/journal.pone.0122795.t003
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found to be associated with higher costs. Consistent with other studies, the most expensive
component of total outpatient costs after physician costs were medications [24, 25, 29, 42].
This rise in cost indicated a growth in the consumption of prescription medications, which
may be due to increase adherence to medications. Evidence has shown that better adherence
results in better healthcare outcomes and reduces the need for physician visits [43, 44], and
lead to a net decrease in overall healthcare cost.
As a prevalence-based cost-of-illness study, the strength of this study was that all DM cases
were included from a specified year, regardless of whether or not they were diagnosed before or
during that year. This breadth allows for analysis of patients at various stages of the illness,
since different severities of DMmay be associated with different costs. However, there were
several limitations in this study. First, data was drawn from a healthcare database, hence relied
on the accuracy and completeness of the records. The NHG CDMS has, however, been used in
several studies and is recognised for providing well-validated and comprehensive data [14, 45].
Second, patients with undiagnosed diabetes as well as indirect/intangible costs and out-of-
pocket expenses were not included, which may contribute to an underestimation of the true
cost of diabetes. Lastly, the study population was relatively small and limited to the public
healthcare sector in Singapore. Future studies may consider these shortcomings to further as-
sess different aspects of diabetes costs.
Conclusion
This study provided a comprehensive cost analysis of expenditures incurred in the treatment
of DM in Singapore. The results indicated that both medications and DM complications were
strong determinants of costs. With projected increase in diabetes prevalence coupled with obe-
sity and growing need for medical treatment in Singapore, diabetes will continue to be a heavy
burden on health budgets. Therefore, evidence on the economic burden related to diabetes-
related complication and its drives are indispensable for a health-system reform that seeks to
minimise the long-term economic burden of this growing epidemic.
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